Mymetics (MYMX) Stock Price, News & Analysis

Company Overview

Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: N/A
• 52-Week Range: $0.0010 to $0.0010
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $152.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MYMX Stock Analysis - Frequently Asked Questions

How have MYMX shares performed this year?

Mymetics' stock was trading at $0.0020 on January 1st, 2024. Since then, MYMX shares have decreased by 50.0% and is now trading at $0.0010.
View the best growth stocks for 2024 here.

How do I buy shares of Mymetics?

Shares of MYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Mymetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mymetics investors own include Dynavax Technologies (DVAX), Fujitsu (FJTSY), Genocea Biosciences (GNCA), Maxar Technologies (MAXR), Revance Therapeutics (RVNC), Axcelis Technologies (ACLS) and Allied Gaming & Entertainment (AGAE).

Company Calendar

• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MYMX
• CUSIP: N/A
• CIK: 927761
• Web: www.mymetics.com
• Phone: (121) 653-4535
• Fax: 41-21-653-2473
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.08 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.23) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 152,000
• Free Float: 144,000
• Market Cap: $152.00
• Optionable: Not Optionable
• Beta: 1.64